Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $11.38.

Several brokerages have commented on CMPX. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Finally, Guggenheim started coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They set a “buy” rating and a $12.00 price target for the company.

Compass Therapeutics Stock Up 2.7 %

NASDAQ CMPX opened at $2.69 on Friday. The firm has a market cap of $371.98 million, a P/E ratio of -7.27 and a beta of 1.19. The company’s 50 day moving average is $2.68 and its 200-day moving average is $1.99. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rovin Capital UT ADV bought a new position in Compass Therapeutics in the third quarter valued at $25,000. Tower Research Capital LLC TRC boosted its holdings in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new position in shares of Compass Therapeutics during the 4th quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics during the 4th quarter valued at about $27,000. Finally, Intech Investment Management LLC bought a new stake in Compass Therapeutics in the 3rd quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.